We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
Stockal+Disclaimer.pdf
2 own
5 watching
Current Price
$0
$0.26
(0.99%)
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
1,879.63M
52-Week High
45.58
52-Week Low
14.85
Average Volume
0.02M
Dividend Yield
--
P/E Ratio
--
Market Capitalization1,879.63M
52-Week High45.58
52-Week Low14.85
Average Volume0.02M
Dividend Yield--
P/E Ratio--
What does the Stockal+Disclaimer.pdf do?
Veracyte, Inc. operates as a molecular diagnostics company in the United States. The company uses genomic technology to resolve diagnostic ambiguity. It offers Afirma Thyroid FNA Analysis solution for use in thyroid cancer diagnosis; cytopathology testing services; and the Afirma Malignancy Classifiers to manage thyroid nodule patients. The company's products also include Percepta Bronchial Genomic Classifier solution for use in lung cancer screening and diagnosis; and Envisia Genomic Classifier solution for idiopathic pulmonary fibrosis. It sells its products through its product specialists, institutional channel managers, account managers, and clinical science specialists. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Read More
How much money does Stockal+Disclaimer.pdf make?
News & Events about Stockal+Disclaimer.pdf.
Ticker Report
21days ago
Veracyte (NASDAQ:VCYT Get Rating) had its target price raised by SVB Leerink from $30.00 to $35.00 in a research report released on Thursday morning, MarketBeat Ratings reports. The firm currently has an outperform rating on the biotechnology companys stock. Other equities research ...
Business Wire
1month ago
Veracyte, Inc. (Nasdaq: VCYT) announced new data demonstrating that a genomic signature derived from the companys Decipher GRID database could help determine which men experiencing prostate cancer progression following radical prostatectomy (RP) would benefit from dose-intensified salvage...
Business Wire
1month ago
Veracyte, Inc. (Nasdaq: VCYT) today announced data that provide new insights into thyroid tumor behavior. The findings were derived from whole-transcriptome analyses of Veracytes extensive thyroid nodule database and were presented at the American Thyroid Association Annual Meeting, held October...
Ticker Report
2 months ago
Diversified Trust Co increased its position in Veracyte, Inc. (NASDAQ:VCYT Get Rating) by 11.6% in the 2nd quarter, according to its most recent filing with the SEC. The fund owned 11,825 shares of the biotechnology companys stock after purchasing an additional 1,225 shares during the...
Business Wire
2 months ago
Veracyte, Inc. (Nasdaq: VCYT) announced that data published today in the Journal of the National Cancer Institute demonstrate that the companys Decipher Prostate Genomic Classifier may help identify African American men with early, localized prostate cancer who are most likely to harbor more...
Frequently Asked Questions
Frequently Asked Questions
What is Stockal+Disclaimer.pdf share price today?
plus_minus_icon
Can Indians buy Stockal+Disclaimer.pdf shares?
plus_minus_icon
How can I buy Stockal+Disclaimer.pdf shares from India?
plus_minus_icon
Can Fractional shares of Stockal+Disclaimer.pdf be purchased?
plus_minus_icon
What are the documents required to start investing in Stockal+Disclaimer.pdf stocks?
plus_minus_icon
What is today’s traded volume of Stockal+Disclaimer.pdf?
plus_minus_icon
What is today’s market capitalisation of Stockal+Disclaimer.pdf?
plus_minus_icon
What is the 52-Week High and Low Range of Stockal+Disclaimer.pdf?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf down from its 52-Week High?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf up from its 52-Week Low?
plus_minus_icon
Current Price
$0
$0.26
(0.99%)
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00